Lazard Capital Upgrades Cubist Pharmaceuticals (CBST) to Buy
Tweet
Share
E-mailGet Alerts CBST Hot Sheet
Price: $101.94 --0%
Rating Summary:
6 Buy, 13 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Rating Summary:
6 Buy, 13 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Join SI Premium – FREE
Lazard Capital upgraded Cubist Pharmaceuticals (NASDAQ: CBST) from Hold to Buy. New PT $33.
For more ratings news on Cubist Pharmaceuticals click here and for the rating history of Cubist Pharmaceuticals click here.
Shares of Cubist Pharmaceuticals closed at $25.25 yesterday.
For more ratings news on Cubist Pharmaceuticals click here and for the rating history of Cubist Pharmaceuticals click here.
Shares of Cubist Pharmaceuticals closed at $25.25 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Upgrades John B. Sanfilippo & Son, Inc. (JBSS) to Buy
- JPMorgan Upgrades Michelin (ML:FP) (MGDDY) to Overweight
- JPMorgan Upgrades BWP Trust (BWP:AU) to Neutral
Create E-mail Alert Related Categories
UpgradesRelated Entities
LazardSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
